{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:59:18Z","timestamp":1792706358687,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T00:00:00Z","timestamp":1372809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s12640-013-9408-1","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T13:56:21Z","timestamp":1372773381000},"page":"523-531","source":"Crossref","is-referenced-by-count":21,"title":["Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice"],"prefix":"10.1007","volume":"24","author":[{"given":"Chu Lan","family":"Lao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsi","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Ting","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"key":"9408_CR1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1743-0003-2-20","volume":"2","author":"I Amende","year":"2005","unstructured":"Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG (2005) Gait dynamics in mouse models of Parkinson\u2019s disease and Huntington\u2019s disease. J Neuroeng Rehabil 2:20","journal-title":"J Neuroeng Rehabil"},{"key":"9408_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0006-8993(01)02466-0","volume":"905","author":"DW Anderson","year":"2001","unstructured":"Anderson DW, Neavin T, Smith JA, Schneider JS (2001) Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 905:44\u201353","journal-title":"Brain Res"},{"key":"9408_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(09)70225-X","volume":"8","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease. Lancet Neurol 8:37\u2013929","journal-title":"Lancet Neurol"},{"key":"9408_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/neu.2009.0914","volume":"26","author":"JE Beare","year":"2009","unstructured":"Beare JE, Morehouse JR, DeVries WH, Enzmann GU, Burke DA, Magnuson DS, Whittemore SR (2009) Gait analysis in normal and spinal contused mice using the TreadScan system. J Neurotrauma 26:56\u20132045","journal-title":"J Neurotrauma"},{"key":"9408_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","volume":"163","author":"JP Bennett Jr","year":"1999","unstructured":"Bennett JP Jr, Piercey MF (1999) Pramipexole\u2013a new dopamine agonist for the treatment of Parkinson\u2019s disease. J Neurol Sci 163:25\u201331","journal-title":"J Neurol Sci"},{"key":"9408_CR36","doi-asserted-by":"crossref","unstructured":"Bhatt J, Subbaiah G, Singh S (2006) Liquid chromatography\/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Comm Mass Spectr 20:2109\u20132114","DOI":"10.1002\/rcm.2537"},{"key":"9408_CR39","doi-asserted-by":"crossref","unstructured":"Blagg J, Allerton CMN, Batchelor DVJ, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S (2007) Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorg Med Chem Lett 17:6691\u20136696","DOI":"10.1016\/j.bmcl.2007.10.059"},{"key":"9408_CR6","first-page":"9","volume":"171","author":"M Bode","year":"2009","unstructured":"Bode M (2009) Dopamine agonist therapy in early Parkinson\u2019s disease. A survey of a Cochrane review. Ugeskr Laeger 171:9\u20132996","journal-title":"Ugeskr Laeger"},{"key":"9408_CR7","first-page":"8","volume":"48","author":"SC Budsberg","year":"1987","unstructured":"Budsberg SC, Verstraete MC, Soutas-Little RW (1987) Force plate analysis of the walking gait in healthy dogs. Am J Vet Res 48:8\u2013915","journal-title":"Am J Vet Res"},{"key":"9408_CR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","volume":"19","author":"RJ Carter","year":"1999","unstructured":"Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington\u2019s disease mutation. J Neurosci 19:57\u20133248","journal-title":"J Neurosci"},{"key":"9408_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","volume":"582","author":"S Chen","year":"2008","unstructured":"Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W (2008) D2\/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett 582:10\u2013603","journal-title":"FEBS Lett"},{"key":"9408_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(02)11668-0","volume":"360","author":"CE Clarke","year":"2002","unstructured":"Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson\u2019s disease. Lancet 360:9\u20131767","journal-title":"Lancet"},{"key":"9408_CR11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jmor.1051460202","volume":"146","author":"AH Cohen","year":"1975","unstructured":"Cohen AH, Gans C (1975) Muscle activity in rat locomotion: movement analysis and electromyography of the flexors and extensors of the elbow. J Morphol 146:96\u2013177","journal-title":"J Morphol"},{"key":"9408_CR42","doi-asserted-by":"crossref","unstructured":"Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH (2009) Intranasal delivery of cells in the brain. Eur J Cell Biol 88:315\u2013324","DOI":"10.1016\/j.ejcb.2009.02.001"},{"key":"9408_CR12","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","volume":"22","author":"F Du","year":"2005","unstructured":"Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422\u20132430","journal-title":"Eur J Neurosci"},{"key":"9408_CR13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-0270(01)00485-X","volume":"113","author":"PO Fernagut","year":"2002","unstructured":"Fernagut PO, Diguet E, Labattu B, Tison F (2002) A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113:123\u2013130","journal-title":"J Neurosci Methods"},{"key":"9408_CR45","doi-asserted-by":"crossref","unstructured":"Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:S3\u2013S5","DOI":"10.1186\/1471-2202-9-S3-S5"},{"key":"9408_CR14","doi-asserted-by":"crossref","first-page":"026113","DOI":"10.1063\/1.3147408","volume":"19","author":"JM Hausdorff","year":"2009","unstructured":"Hausdorff JM (2009) Gait dynamics in Parkinson\u2019s disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos 19:026113","journal-title":"Chaos"},{"key":"9408_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(99)01688-1","volume":"838","author":"M Iida","year":"1999","unstructured":"Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51\u201359","journal-title":"Brain Res"},{"key":"9408_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","volume":"56","author":"L Illum","year":"2004","unstructured":"Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3\u201317","journal-title":"J Pharm Pharmacol"},{"key":"9408_CR17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuint.2009.07.009","volume":"55","author":"M Inden","year":"2009","unstructured":"Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 55:760\u2013767","journal-title":"Neurochem Int"},{"key":"9408_CR18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1471-4159.2005.03625.x","volume":"96","author":"MM Iravani","year":"2006","unstructured":"Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH (2006) Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96:1315\u20131321","journal-title":"J Neurochem"},{"key":"9408_CR19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368\u2013376","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9408_CR20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2006.11.004","volume":"7","author":"JN Joyce","year":"2007","unstructured":"Joyce JN, Millan MJ (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson\u2019s disease. Curr Opin Pharmacol 7:100\u2013105","journal-title":"Curr Opin Pharmacol"},{"key":"9408_CR21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1742-1241.2011.02793.x","volume":"65","author":"K Kalinderi","year":"2011","unstructured":"Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S (2011) Pharmacological treatment and the prospect of pharmacogenetics in Parkinson\u2019s disease. Int J Clin Pract 65:1289\u20131294","journal-title":"Int J Clin Pract"},{"key":"9408_CR22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/glia.22449","volume":"61","author":"CL Lao","year":"2013","unstructured":"Lao CL, Lu CS, Chen JC (2013) Dopamine D(3) receptor activation promotes neural stem\/progenitor cell proliferation through AKT and ERK1\/2 pathways and expands type-B and -C cells in adult subventricular zone. Glia 61:475\u2013489","journal-title":"Glia"},{"key":"9408_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10611869808997870","volume":"5","author":"S Mathison","year":"1998","unstructured":"Mathison S, Nagilla R, Kompella UB (1998) Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 5:415\u2013441","journal-title":"J Drug Target"},{"key":"9408_CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2007.05.030","volume":"1160","author":"N Matsukawa","year":"2007","unstructured":"Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV (2007) Overexpression of D2\/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Res 1160:113\u2013123","journal-title":"Brain Res"},{"key":"9408_CR25","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1002\/ana.410440206","volume":"44","author":"CW Olanow","year":"1998","unstructured":"Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson\u2019s disease. Ann Neurol 44:S167\u2013S174","journal-title":"Ann Neurol"},{"key":"9408_CR26","first-page":"141","volume":"21","author":"MF Piercey","year":"1998","unstructured":"Piercey MF (1998) Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson\u2019s disease. Clin Neuropharmacol 21:141\u2013151","journal-title":"Clin Neuropharmacol"},{"key":"9408_CR27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, Fortuna A, Alves G, Falcao A (2009) Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 12:288\u2013311","journal-title":"J Pharm Pharm Sci"},{"key":"9408_CR28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12640-009-9087-0","volume":"17","author":"RD Prediger","year":"2010","unstructured":"Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, Chevarin C, Bel ED, Mongeau R, Hamon M, Lanfumey L, Raisman-Vozari R (2010) Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice models early preclinical phase of Parkinson\u2019s disease. Neurotox Res 17:114\u2013129","journal-title":"Neurotox Res"},{"key":"9408_CR48","doi-asserted-by":"crossref","unstructured":"Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440\u2013448","DOI":"10.1212\/01.WNL.0000265401.62434.36"},{"key":"9408_CR29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.111.040782","volume":"39","author":"J Stevens","year":"2011","unstructured":"Stevens J, Ploeger BA, van der Graaf PH, Danhof M, de Lange EC (2011) Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos 39:2275\u20132282","journal-title":"Drug Metab Dispos"},{"key":"9408_CR30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","volume":"83","author":"B Thanvi","year":"2007","unstructured":"Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83:384\u2013388","journal-title":"Postgrad Med J"},{"key":"9408_CR31","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1523\/JNEUROSCI.0837-06.2006","volume":"26","author":"JM Kampen Van","year":"2006","unstructured":"Van Kampen JM, Eckman CB (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson\u2019s disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26:7272\u20137280","journal-title":"J Neurosci"},{"key":"9408_CR32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.0953-816X.2004.03342.x","volume":"19","author":"JM Kampen Van","year":"2004","unstructured":"Van Kampen JM, Hagg T, Robertson HA (2004) Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci 19:2377\u20132387","journal-title":"Eur J Neurosci"},{"key":"9408_CR33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0024-3205(99)00062-4","volume":"64","author":"L Zou","year":"1999","unstructured":"Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W (1999) Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 64:1275\u20131285","journal-title":"Life Sci"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-013-9408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-013-9408-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-013-9408-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T23:14:38Z","timestamp":1563318878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-013-9408-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,3]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["9408"],"URL":"https:\/\/doi.org\/10.1007\/s12640-013-9408-1","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,3]]}}}